ClinicalTrials.gg
TerminatedNCT00748579Updated Jan 21, 2020Results posted

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

A Phase 2 interventional study of CK-1827452 and CK-1827452 in Heart Failure, sponsored by Cytokinetics. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-21.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision to discontinue due to challenges of trial design and constraints on enrolling eligible and consenting patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
12th of 14
2 · median 48
Started
2008
with 1 other
Phase 2
7 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 12th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 2nd registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with heart failure.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indication for left and right heart catheterization
  • Willing and able to provide
  • Male or female 18 years of age or greater
  • Symptomatic heart failure (≥ Class II)
  • ≤ 35%
  • Patient is in sinus rhythm
  • Patient is considered to be in suitable health in the opinion of the investigator, as determined by:

    o A pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure

  • For female patients only: or sterilized, or if she is of , she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant for up to 90 days following the study, and she is using drugs or devices

Exclusion criteria

Exclusion Criteria:

  • Acute myocarditis
  • Hypertrophic, restrictive, or constrictive cardiomyopathy
  • Congenital heart disease
  • Known left ventricular thrombus
  • Significant stenotic valvular disease (severe aortic stenosis, mitral stenosis)
  • Poorly controlled hypertension (SBP > 180 mmHg)
  • Pacemaker dependent ventricular rhythm
  • Detectable troponin or CK-MB > at any timepoint within 14 days of enrollment
  • Acute coronary syndrome or revascularization procedure within 30 days of enrollment
  • ≥ 50% stenosis of the left main coronary artery
  • Plan for immediate revascularization procedure (PCI or CABG)
  • ≤ 35 ml/min/1.73 m2 by Modification of Diet in Renal Disease (MDRD) Equation or need for renal replacement therapy
  • Known hepatic impairment (total > 3 mg/dL, or and AST > 2 times the upper limit of normal)
  • Has received an drug or device within 30 days before enrollment
  • Has had any prior treatment with CK-1827452
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Cohort 1

    0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452

    Drug: CK-1827452

  • Experimental
    Cohort 2

    ≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452

    Drug: CK-1827452

Interventions

  • I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr

  • I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr

06

What researchers measure

Primary outcomes

  1. Effect of CK-1827452 on Myocardial Efficiency, Defined as the Ratio of Ventricular Performance to Myocardial Oxygen Consumption.

    Measure the effect CK-1827452 on hemodynamics and energetic measures of ventricular performance, myocardial oxygen consumption, and myocardial efficiency (the ratio of ventricular performance to myocardial oxygen consumption), in patients with clinical heart failure.

    Time frame: 1 day

Secondary outcomes

  1. Effects of CK-1827452 on Ventricular Performance

    Measure the effect of CK-1824752 on ventricular performance

    Time frame: 1 day

  2. Effects of CK-1827452 on Myocardial Oxygen Consumption

    Measure the effect of CK-1824752 on myocardial oxygen consumption

    Time frame: 1 day

  3. Effects of CK-1827452 on Pressure-volume Relationships

    Measure the effect of CK-1824752 on pressure-volume relationships

    Time frame: 1 day

  4. Effects of CK-1827452 on Systolic Ejection Time

    Measure the effect of CK-1824752 on systolic ejection time

    Time frame: 1 day

  5. Effects of CK-1827452 on Invasively Measured Hemodynamics, Including Filling Pressure and Cardiac Output

    Measure the effect of CK-1824752 on invasively measured hemodynamics, including filling pressure and cardiac output

    Time frame: 1 day

07

Results

Posted Aug 23, 2010
Limitations and caveats
Inadequate enrollment led to early termination of study and insufficient number of patients for analysis.

Participant flow

The recruitment period was from September 2008 to July 2009.

Participant flow — Overall Study
MilestoneMid Dose CK-1827452 (Cohort 1)High Dose CK-1827452 (Cohort 2)
Started20
Completed20
Not completed00

Outcome measures

PrimaryEffect of CK-1827452 on Myocardial Efficiency, Defined as the Ratio of Ventricular Performance to Myocardial Oxygen Consumption.

Measure the effect CK-1827452 on hemodynamics and energetic measures of ventricular performance, myocardial oxygen consumption, and myocardial efficiency (the ratio of ventricular performance to myocardial oxygen consumption), in patients with clinical heart failure.

Time frame:
1 day

No measurements were reported for this outcome.

SecondaryEffects of CK-1827452 on Ventricular Performance

Measure the effect of CK-1824752 on ventricular performance

Time frame:
1 day

No measurements were reported for this outcome.

SecondaryEffects of CK-1827452 on Myocardial Oxygen Consumption

Measure the effect of CK-1824752 on myocardial oxygen consumption

Time frame:
1 day

No measurements were reported for this outcome.

SecondaryEffects of CK-1827452 on Pressure-volume Relationships

Measure the effect of CK-1824752 on pressure-volume relationships

Time frame:
1 day

No measurements were reported for this outcome.

SecondaryEffects of CK-1827452 on Systolic Ejection Time

Measure the effect of CK-1824752 on systolic ejection time

Time frame:
1 day

No measurements were reported for this outcome.

SecondaryEffects of CK-1827452 on Invasively Measured Hemodynamics, Including Filling Pressure and Cardiac Output

Measure the effect of CK-1824752 on invasively measured hemodynamics, including filling pressure and cardiac output

Time frame:
1 day

No measurements were reported for this outcome.

Adverse events

Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mid Dose CK-1827452 (Cohort 1)—0/2 (0%)2/2 (100%)
High Dose CK-1827452 (Cohort 2)———
Most frequent other events
Most frequent other events
EventMid Dose CK-1827452 (Cohort 1)High Dose CK-1827452 (Cohort 2)
Troponin IncreasedInvestigations2/2—
Supraventricular TachycardiaCardiac disorders1/2—

Baseline characteristics

Study was terminated due to challenges of trial design and constraints on enrolling eligible and consenting patients

Age, Categorical
Age, Categorical(Participants)Mid Dose CK-1827452 (Cohort 1)High Dose CK-1827452 (Cohort 2)Total
<=18 years0—0
Between 18 and 65 years1—1
>=65 years1—1
Age, Continuous
Age, Continuous(years)Mid Dose CK-1827452 (Cohort 1)High Dose CK-1827452 (Cohort 2)Total
Mean69 ± 13—69 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Mid Dose CK-1827452 (Cohort 1)High Dose CK-1827452 (Cohort 2)Total
Female2—2
Male0—0
Region of Enrollment
Region of Enrollment(participants)Mid Dose CK-1827452 (Cohort 1)High Dose CK-1827452 (Cohort 2)Total
United States2—2
08

Study locations

3 sites
  • Johns Hopkins Medical Institutions
    Baltimore, Maryland 21205, United States
  • UUHSC / Division of Cardiology
    Salt Lake City, Utah 84132, United States
  • Mount Sinai Hospital
    Toronto, Ontario M5G 1X5, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Nov 2008 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2008
First posted
Sep 8, 2008
Start
Sep 2008
Primary completionActual
Nov 2008
CompletionActual
Jul 2009
Results first posted
Aug 23, 2010
Last update
Jan 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00748579
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Sep 8, 2008
Start date
Sep 2008
Primary completion
Nov 2008
Completion
Jul 2009
Results posted
Aug 23, 2010
Last update
Jan 21, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion